FDA stalls yet an­oth­er Her­ceptin copy­cat, is­su­ing re­sponse let­ter to Am­gen/Al­ler­gan

In a some­what un­sur­pris­ing set­back, Am­gen $AMGN and its part­ner Al­ler­gan got snubbed by the FDA Fri­day on the duo’s biosim­i­lar ap­pli­ca­tion for their Her­ceptin …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER